Emboldened Government Pursuit and Prosecution of Healthcare Fraud and Abuse

In recent years, the Department of Justice (“DOJ”) and the Office of the Inspector General (“OIG”) have demonstrated an increased willingness to use the tools which Congress has provided them in order to combat healthcare fraud and abuse. Primarily, these tools consist of: (1) the Anti-Kickback Statute (“AKS”); (2) the Stark Law (“Stark”); and, (3) the False Claims Act (“FCA”). The AKS makes it a felony for any person to knowingly and willfully solicit, offer, receive, or pay any remuneration in exchange for the referral of a patient for healthcare services paid by a federal healthcare program. On the other hand, Stark prohibits physicians or immediate family members of physicians from referring Medicare or Medicaid patients to an entity for a designated health service, if the physician or a family member has a financial relationship with that entity. Finally, the FCA creates civil liability for any person who knowingly presents a false or fraudulent claim for payment to an officer or employee of the United States for payment or approval. Using the FCA in conjunction with either of the other laws, particularly Stark, presents a formidable tool for the government in policing healthcare fraud and abuse, especially because the FCA contains a whistleblower provision. This whistleblower provision allows any private citizen to enforce the FCA by filing a qui tam action against an entity on behalf of the government. The government may then intervene, and assume primary responsibility for prosecuting the lawsuit, and the whistleblower, the private citizen who instigated the proceedings, may recover a portion of any damages that the government recovers.

Since 1998, the government agencies responsible for prosecuting healthcare fraud and abuse, the DOJ and OIG, have demonstrated an increased willingness to pursue claims under the AKS, Stark, and FCA, as well as to prosecute increasingly complicated sets of violations. Part one of this three part series introduces the statutory and regulatory framework of relevant statutes, the teams responsible for investigating healthcare fraud and abuse, and relevant theoretical concepts involved in healthcare fraud and abuse lawsuits. Part two of this series, scheduled to be released in the monthly January 2014 issue of Health Capital Topics, will discuss certain notable violations of the above-mentioned statutes. Part three of this series, scheduled to be released in the monthly February 2014 issue of Health Capital Topics, will explore how the DOJ and OIG are prosecuting increasingly complex lawsuits and dramatically influencing the level of payment utilized in establishing Fair Market Value (“FMV”) and Commercial Reasonableness (“CR”).

Recently, a variety of investigatory programs and teams have been established to assist the DOJ and OIG in identifying and pursuing healthcare fraud and abuse claims. In 2005, the Recovery Audit Contractors (“RAC”) program was established, and was tasked with identifying improper Medicare overpayments and underpayments by monitoring: (1) payments for medically unnecessary services; (2) payments for incorrectly coded services; and, (3) payments for services not supported by sufficient documentation. During its three-year demonstration period, the RAC Program recovered $1.03 billion in improper Medicare payments, and, subsequently, Congress required that the RAC program be permanently established in all 50 states by January 1, 2010. In 2008, the Centers for Medicare & Medicaid Services (“CMS”) awarded contracts to four commercial RAC auditing firms, each responsible for a specified region of the United States. In addition to the RAC program, CMS created the Comprehensive Error Rate Testing (“CERT”) program in order to determine improper Medicare fee-for-service payments. CMS utilizes CERT’s results to provide Congress with an estimate of the annual amount of improper Medicare payments made to providers throughout the year.

On May 20, 2009, President Barack Obama signed the Fraud Enforcement and Recovery Act (“FERA”), which reduced the government’s burden of proof in FCA cases by no longer requiring the government to show a person’s specific intent to defraud in determining liability. Also in May of 2009, the Department of Health and Human Services (“HHS”) and DOJ established the Healthcare Fraud Prevention and Enforcement Action Team (“HEAT”) with funds from President Obama’s budget. HEAT focuses on investigating and identifying patterns of potentially fraudulent activity. Since it its January 2009 inception, HEAT has recovered over $6.6 billion for the federal government under the FCA. Finally, the Medicare Fraud Strike Force, another HHS-DOJ collaboration founded in 2007, performs investigatory functions
similar to HEAT. As a result of HEAT and Medicare Fraud Strike Force collaboration, the Medicare Fraud Strike Force identified and investigated one of the largest healthcare fraud recoveries to date, eventually charging 107 medical professionals for fraudulently billing Medicare over $452 billion.\textsuperscript{14}

Once healthcare fraud has been identified, the OIG and DOJ must prosecute the claim. As mentioned above, the AKS makes it a felony for any person to knowingly and willfully solicit, offer, receive, or pay any remuneration in exchange for the referral of a patient for healthcare services paid by a federal healthcare program.\textsuperscript{15} There are, however, a number of “safe harbors” to the definition of remuneration.\textsuperscript{16} Strict compliance with a safe harbor will preempt the OIG and DOJ from pursuing a claim based on an AKS violation; however, in instances where an entity does not strictly comply with a safe harbor, the OIG has stated that it will evaluate the facts and circumstances specific to every agreement in order to determine violation of the AKS.\textsuperscript{17} Specifically, the OIG has assessed: (1) whether compensation for the services provided was at fair market value; (2) whether the compensation paid varied with the number of patients treated; (3) whether or not parties intended compensation to be offered for referrals; (4) the specificity of quality component measures within the agreement; and, (5) whether or not the agreement was for a limited duration.\textsuperscript{18}

The majority of recent claims have involved qui tam whistleblowers alleging that entities have violated the FCA through violating Stark’s prohibition of physician self-referral. As mentioned above, Stark prohibits physicians or immediate family members of physicians from referring Medicare or Medicaid patients to an entity, e.g., a hospital, for a designated health service (“DHS”) if the physician or a family member of the physician has a financial relationship with that entity.\textsuperscript{19} The Centers for Medicare & Medicaid Services (“CMS”) promulgated a list of 10 types of DHS, the most notable of which, for the purposes of this series, are “inpatient and outpatient hospital services.”\textsuperscript{20} because the majority of cases arising under Stark result from hospitals billing for inpatient and/or outpatient hospital services. Financial relationships are defined as any ownership, investment, or compensation agreement with an entity, unless otherwise covered by an exception.\textsuperscript{21} There are also 27 separate Stark exceptions.\textsuperscript{22} Therefore, in lawsuits alleging violations of Stark, the government must prove each element of a Stark violation: (1) a financial relationship between the physician and entity; (2) a referral for a designated health service by the physician to the entity; and, (3) submission of the claim associated with the referral by the entity to Medicare or Medicaid for the designated health service.\textsuperscript{23} If and when the government demonstrates proof of each element of a Stark violation, the burden shifts to the defendant to establish that its financial relationship or conduct was protected by a Stark exception.\textsuperscript{24}

Much of the argument in a Stark lawsuit centers on whether or not an entity’s relationship with a physician fulfills the requirements of a Stark exception. The majority of these Stark exceptions require that any reimbursement paid by the entity to the physician be consistent with FMV and commercially reasonable,\textsuperscript{25} and, therefore, much of the argument centers on whether compensation provided to physicians was consistent with FMV.

In addition to Stark violations, payment in excess of FMV for the purchase of physician practices also violates the AKS prohibition against payment for referrals.\textsuperscript{26} Congress and various government agencies have promulgated definitions of FMV and CR, the most relevant of which are:

\begin{quote} 
“...fair market value in arms-length transactions...not determined in a manner that takes into account the volume or value of any referrals or business otherwise generated between the parties for which payment may be made in whole or in part under Medicare or a State health care program.”\textsuperscript{27}

“Fair market value means the value in arm’s-length transactions, consistent with the general market value. General market value means the price that an asset would bring as the result of bona fide bargaining between well-informed buyers and sellers who are not otherwise in a position to generate business for the other party, or the compensation that would be included in a service agreement as the result of bona fide bargaining between well-informed parties to the agreement who are not otherwise in a position to generate business for the other party, on the date of acquisition of the asset or at the time of the service agreement.”\textsuperscript{28}

“We believe the relevant comparison is aggregate compensation paid to physicians practicing in similar academic settings located in similar environments. Relevant factors include geographic location, size of the academic institutions, scope of clinical and academic programs offered, and the nature of the local health care marketplace... we intend to accept any method [for establishing FMV] that is commercially reasonable and provides us with evidence that the compensation is comparable to what is ordinarily paid for an item or service in the location

\end{quote}
Once it is determined that Stark, or the AKS, was violated, the government continues with its FCA analysis. Specifically, the FCA requires that: (1) a false or fraudulent claim (2) was presented by the defendant to the United States for payment or approval (3) with knowledge that the claim was false. Any claim that (1) violates Stark or the AKS and (2) is presented to a government program for payment is also false and/or fraudulent because entities submitting claims for payment under Medicare or Medicaid must certify compliance with any applicable laws as a pre-condition to receiving payment. Therefore, in addition to Stark violations the government need only prove that an entity knowingly violated Stark in order to recover under the FCA.

The majority of fraud and abuse cases analyzed within the subsequent parts of this series follow the aforementioned statutory and regulatory framework, with a particular focus on Stark violations, exceptions, and a FMV and CR analysis.

1. “Criminal Penalties for Acts Involving Federal Health Care Programs” 42 U.S.C. § 1320a-7b(b)
2. “Limitations on certain physician referrals” 42 U.S.C. § 1395nn(a)
4. Ibid, 31 U.S. § 3730(b)
5. Ibid, 31 U.S.C. §§ 3730(c)(1), § 3730(d)(1)
15. Ibid, 42 U.S.C. § 1320a-7b(b)
18. Ibid
19. Ibid, 42 U.S.C. § 1395nn(a)
22. Ibid, 42 U.S.C. § 1395nn(b)-(c); “General exceptions to the referral prohibition related to both ownership/investment and compensation” 42 C.F.R. § 411.355(a)(i); “Exceptions to the referral prohibition related to ownership or investment interests” 42 C.F.R. § 411.356(a)-(c); “Exceptions to the referral prohibition related to compensation arrangements” 42 C.F.R. § 411.357(a)-(p)
23. USA ex rel. Elin Baklid-Kunz v. Halifax Hospital Medical Center”, Order, No. 6:09-cv-01002-GAP-TBS (M.D. Fla. Nov. 11, 2013), ECF No. 396, p. 10
24. Ibid
27. “Program Integrity; Medicare and State Health Care Programs; Permissive Exclusions” 42 C.F.R. § 1001.952(5)
28. “Medicare and Medicaid Programs; Physicians’ Referrals to Health Care Entities with Which they Have Financial Relationships (Phase III); Final Rule” Federal Register Vol. 72, No. 171 (September 5, 2007), p. 51081
Robert James Cimasi, MHA, ASA, FRICS, MCBA, AVA, CM&AA, serves as Chief Executive Officer of Health Capital Consultants (HCC), a nationally recognized healthcare financial and economic consulting firm headquartered in St. Louis, MO, serving clients in 49 states since 1993. Mr. Cimasi has over thirty years of experience in serving clients, with a professional focus on the financial and economic aspects of healthcare service sector entities including: valuation consulting and capital formation services; healthcare industry transactions including joint ventures, mergers, acquisitions, and divestitures; litigation support & expert testimony; and, certificate-of-need and other regulatory and policy planning consulting.

Mr. Cimasi holds a Masters in Health Administration from the University of Maryland, as well as several professional designations: Accredited Senior Appraiser (ASA – American Society of Appraisers); Fellow Royal Intuition of Chartered Surveyors (FRICS – Royal Institute of Chartered Surveyors); Master Certified Business Appraiser (MCBA – Institute of Business Appraisers); Accredited Valuation Analyst (AVA – National Association of Certified Valuators and Analysts); and, Certified Merger & Acquisition Advisor (CM&AA – Alliance of Merger & Acquisition Advisors). He has served as an expert witness on cases in numerous courts, and has provided testimony before federal and state legislative committees. He is a nationally known speaker on healthcare industry topics, the author of several books, the latest of which include: “Accountable Care Organizations: Value Metrics and Capital Formation” [2013 - Taylor & Francis, a division of CRC Press], “The Adviser’s Guide to Healthcare” – Vols. I, II & III [2010 – AICPA], and “The U.S. Healthcare Certificate of Need Sourcebook” [2005 - Beard Books]. His most recent book, entitled “Healthcare Valuation: The Financial Appraisal of Enterprises, Assets, and Services” will be published by John Wiley & Sons in the Fall of 2013.

Mr. Cimasi is the author of numerous additional chapters in anthologies; books, and legal treatises; published articles in peer reviewed and industry trade journals; research papers and case studies; and, is often quoted by healthcare industry press. In 2006, Mr. Cimasi was honored with the prestigious “Shannon Pratt Award in Business Valuation” conferred by the Institute of Business Appraisers. Mr. Cimasi serves on the Editorial Board of the Business Appraisals Practice of the Institute of Business Appraisers, of which he is a member of the College of Fellows. In 2011, he was named a Fellow of the Royal Institution of Chartered Surveyors (RICS).

Todd A. Zigrang, MBA, MHA, ASA, FACHE, is the President of Health Capital Consultants (HCC), where he focuses on the areas valuation and financial analysis for hospitals and other healthcare enterprises. Mr. Zigrang has significant physician integration and financial analysis experience, and has participated in the development of a physician-owned multi-specialty MSO and networks involving a wide range of specialties; physician-owned hospitals, as well as several limited liability companies for the purpose of acquiring acute care and specialty hospitals, ASCs and other ancillary facilities; participated in the evaluation and negotiation of managed care contracts, performed and assisted in the valuation of various healthcare entities and related litigation support engagements; created pro-forma financials; written business plans; conducted a range of industry research; completed due diligence practice analysis; oversee the selection process for vendors, contractors, and architects; and, worked on the arrangement of financing.

Mr. Zigrang holds a Master of Science in Health Administration and a Masters in Business Administration from the University of Missouri at Columbia. He is a Fellow of the American College of Healthcare Executives, and serves as President of the St. Louis Chapter of the American Society of Appraisers (ASA). He has co-authored “Research and Financial Benchmarking in the Healthcare Industry” (STP Financial Management) and “Healthcare Industry Research and its Application in Financial Consulting” (Aspen Publishers). He has additionally taught before the Institute of Business Appraisers and CPA Leadership Institute, and has presented healthcare industry valuation related research papers before the Healthcare Financial Management Association; the National CPA Health Care Adviser’s Association; Association for Corporate Growth; Infocast Executive Education Series; the St. Louis Business Valuation Roundtable; and, Physician Hospitals of America.

Anne P. Sharamitaro, Esq., is the Executive Vice President & General Counsel of Health Capital Consultants (HCC), where she focuses on the areas of Certificate of Need (CON); regulatory compliance, managed care, and antitrust consulting. Ms. Sharamitaro is a member of the Missouri Bar and holds a J.D. and Health Law Certificate from Saint Louis University School of Law, where she served as an editor for the Journal of Health Law, published by the American Health Lawyers Association. Ms. Sharamitaro has presented healthcare industry related research papers before Physician Hospitals of America and the National Association of Certified Valuation Analysts and co-authored chapters in “Healthcare Organizations: Financial Management Strategies,” published in 2008.